Treatment Goals, Side Effects, and Supportive Care Strategies for Patients and Caregivers with HER2+ BC

Opinion
Video

Experts discuss how, discuss patient experiences with an oral chemotherapy regimen, highlighting benefits like treatment autonomy, challenges such as pill burden and gastrointestinal toxicities, and the importance of proactive side effect management and patient education.

Video content above is prompted by the following:

  • What has been your experience with oral regimens and managing toxicities and getting women acclimated to it?

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
Related Content
Anatomical graphic of a person with a tumor in their left breast

First-Line T-DXd/Pertuzumab Yields Improved PFS in HER2+ mBC

Russ Conroy
June 4th 2025
Article

The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.

Graphic of a breast with a tumor.

Q&A: Strong Treatment Choices Can Build Trust in Patients With ESR1+ mBC

Bridget Hoyt
May 22nd 2025
Article

Selecting the right treatment path for a patient with an ESR1 mutation in metastatic breast cancer can help build trust.

Line illustration of a breast on a yellow background

How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC

Kimberly Podsada, BSN, RN, MSN, NP-C, CNS
May 16th 2025
Article

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.

Illustration of two people in lab coats doing work at a desk and at a microscope with a breast icon behind

Avutometinib Triplet Active in Resistant HR+/HER2– Breast Cancer

Jax DiEugenio
May 7th 2025
Article

Early trial data show 13.3% objective response with avutometinib, abemaciclib, and fulvestrant in HR+/HER2– breast cancer resistant to CDK4/6 inhibitors.

Anatomic image of a breast

T-DXd Plus Pertuzumab Improves PFS Over THP in HER2+ Metastatic Breast Cancer

Ashling Wahner
April 23rd 2025
Article
Side profile anatomical rendering of a person, with breast tissue and a breast tumor in orange

Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype

Ashley Chan
March 25th 2025
Article